Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced the enrollment of the first patient into the Lutonix Below the Knee (BTK) Clinical Trial at The Cardiac and Vascular Institute in Gainesville, Florida. The purpose of this pivotal global, multi-center randomized Investigational Device Exemption (IDE) trial is to compare the safety and effectiveness of the Lutonix® 014 Drug Coated PTA Dilatation Catheter to a standard angioplasty balloon for the treatment of critical limb ischemia.
Help employers find you! Check out all the jobs and post your resume.
